I’m a Pediatric Cardiac Anesthesiologist by trade with a keen interest in in-depth analyses of phenomena and processes which lead to clever solutions to technical and business challenges. I received a B.S. degree summa cum laude in Molecular Biophysics and Biochemistry from Yale College and an M.D. degree from Yale University School of Medicine; in addition, I hold M.S. degrees in Electrical Engineering, Mechanical Engineering, and Aeronautics and Astronautics from Stanford University School of Engineering.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our Editorial Team is comprised of individuals with a strong background in science, medicine and the business of successfully commercializing therapeutics, medical devices, diagnostics and healthcare services. Our ultimate objective is to leverage the knowledge, experience, and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector.
Successfully trading, and investing in emerging growth healthcare companies is a difficult task. Over 90% of drugs never make it out of the clinic. Huge capital requirements along the way result in highly dilutive equity financings often done on the backs of retail investors. At PropThink, we believe that due diligence is the key to success in this industry. We leverage a combined 50 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis and due diligence process defines our editorial strategy and provides our subscribers a high level of confidence in our research. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued.
Visit PropThink.com to see all of our coverage and research, and subscribe to our free newsletter to receive reports, articles, and trading alerts.
George H. Brooks
7925 Looking Glass Court
Raleigh, NC 27612
Timing trends, tops and bottoms in the stock market, individual stocks. Hundred thousand chart interpretations.
Telling the small company story. Hundreds of research recommendations.
Analytical Focus: Entire spectrum - technical, fundamental, monetary, psychological, political, and seasonal analysis. Am a contrary thinker, at extremes..
No-nonsense communication, bypassing overused jargon, boiling down indicators and complex issues into understandable terms, highlighting emotional/psychological forces dictating trends and turns, sharing savvy gained from hundreds of thousands of chart interpretations, market calls, personal investments in an enormously dynamic and varied investment environment (1962 – current). Seek creativity to enhance readability and educate reader, inject humor where possible.
I started as a stock broker in 1962 but gravitated to research in 1966 with an ultimate goal of writing about everything related to the stock market, but especially producing daily market forecasts released before the open. I wanted to be the one in the trench calling the shots.
It was an unrealistic goal, since I was vastly short on the knowledge needed to write or analyze. This was what I wanted to do, everything about it fascinated me, so I undertook a huge self-study program scrounging desks in broker’s boardrooms where I could study and trade a modest account for a living. Readings encompassed more than 70 publications covering fundamental and technical analysis. I chose dozens of indicators to study on a daily basis to determine their usefulness and accuracy. I subscribed to chart services, but plotted many by hand.
My early years pre-dated quote machines, so I was forced to become an astute tape reader, which I found to give me an invaluable feel for market action, trends and turns, posting my charts manually each day.
It was a great training ground and absolutely necessary for a person who wanted to write and produce daily commentary before the open, but costly at times when trading profits fell short of expenses.
In 1970, Wright Investor’s Service offered me a job as an analyst with a promise to contribute the timing of purchases and sales for managed accounts. Additionally, it offered me a chance to round out areas I needed a better understanding – fundamental analysis. Wright was an investment publisher and institutional money manager. After an intense indoctrination to Wright’s financial statement analysis, I headed up its Statistics, Economic and Stock Market Studies department supervising a staff of six and reporting directly to the president, John Winthrop Wright. Unfortunately for both of us, Wright was becoming heavily computerized and that included the timing of the stock market and transactions.
As a result, I started my own firm in 1974 providing written analysis, editorial responsibilities and market timing for investment advisory publishers, brokerage firms, magazines, and small companies. This led down many paths
Was the primary contributor of written analysis and stock selections for leading investment advisory publishers throughout the 1970s and 1990s. At one time, I wrote for four different advisories.
Provided Special Situation research for regional broker.
Registered represented with regional brokerage firms in addition to analytical work.
Frequent guest analyst appearances CNBC-TV
Market strategist two regional NYSE brokerage firms, producing daily market analysis and stock selections, and a monthly letter to clients 1970s – 1990s..
Research Profiles telling the small cap company story. – “Companies on the Move>”
In late 2007, I saw the unfolding bear market as an irresistible opportunity to return to published daily market analysis by helping readers first survive the meltdown, then capitalize on a bear market bottom. Targeted the three bottoms to-the-day (October 10, and November 21, 2008 and March 10, 2009. Summary of major calls available in chart form, all 1,000 + posts available.
Publish “Investor’s first read.com,” a daily pre-open analysis of the prospects for the stock market. I published it originally as “Brooksie’s Daily Stock Market blog.” Posted on equities.com's web site 9:15 a.m.
In 1981 Allen founded Allen and Caron, which now has offices in Irvine, California, and New York City, with affiliates in London and Milan. He spent the 1970s in various areas of media and communications. Initially he was an editor and later a marketing manager for scholarly and educational book publishers; he then moved on to serve in the cutting-edge public affairs department at Atlantic Richfield Company in the mid-1970s. When he left Atlantic Richfield, he became vice president and general manager of the southern California region of Bozell & Jacobs Public Relations.
Allen has served on the boards of several small companies, including Westergaard.com, the publishing enterprise of the late John Westergaard. He is the co-author of a college text on system life cycles and books on business communications and continuing education. He has written a book on sandcastles, and has written on a variety of topics for numerous leading magazines and newspapers, and has been active in several charities. He is currently working on a family memoir and a novel.
Allen has also been a contributing author for the "Inside the Minds" series of C-Level Business Intelligence™ books published by Aspatore Books, a Thomson Reuters business. His contributions include a chapter in Public Relations Leadership Strategies titled Investor Relations: Creating a Dialogue with the Investor and a chapter in Public Relations Best Practices 2008-2009 titled Cross-Border Companies: A Fast-Increasing Trend in Investor Relations.
Grant Zeng has over 10 years of professional experience in equity research and analysis. Grant joined Zacks Investment Research Inc. in March 2006, and currently is a senior equity analyst covering biotech/pharma industry. Before joining Zacks, Grant worked for TheStreet.com as a biotech analyst from 2005-2006. From Sept 2001 to December 2003, Grant worked for China Pacific Insurance Co. as an senior equity/fund analyst. Grant was a healthcare equity analyst with Young & Partners, LLC from Aug 2000 to September 2001. Grant had also teaching and researching experience in pharmaceutical science.
Grant Zeng obtained his MBA with a major in Finance in 2000 from McMaster University, Canada. He also holds a Master of Science in Biochemistry from the University of Western Ontario, Canada; Master of Pharmacology and Bachelor of Medicine from Second Military Medical University, China.
Grant Zeng is a Chartered Financial Analyst (CFA) charter holder.
I have a PhD in political science and have been investing for well over a decade. I generally follow small cap biotechnology, MLPs, and mining companies. I hope to provide my thoughts on both topics of interest to investors and particular companies.
See all of my reports at www.sobekanalytics.com
Follow me on twitter: @dsobek.
I hold multiple undergraduate degrees with concentrated focus in the fields of Psychology, Sociology, History, and Economics. Prior to working as an independent strategist for a handful of clients, I was employed as a behavioral economist for a private London based group. Before that, I worked for domestic entities such as FBR and ACC Capital.
In terms of equities analysis, my focus is strictly on long term investments, emerging biotechnology entities, distressed or undervalued companies, and maritime commerce. In terms of market analysis, my focus is on the market implications of social and non-traditional factors. I do not discredit more traditional technical and fundamental analysis, but I value greatly the largely underrated, and often forgotten, historical evolution of capitalism and capital market psychology. Thus, some articles I write will be highly speculative and unorthodox, and will likely represent a minority opinion. Others, when undervaluation is a motivating factor for the article having been written, will be highly technical and metric based.
Also, I urge readers to consider the premise of investment horizon, and authorship intention, when reading my contributions. Many of the articles for companies which I endorse will be deemed "long term", which I generally consider to be no less than 2-3 years unless otherwise noted. Moreover, some articles are written simply to test a potential investment thesis in an effort to garner feedback about prospective positions. In the latter, the "Risk" segment of articles will be thoroughly detailed and should be heavily weighed. Many such pieces will be long "ideas", not necessarily long "recommendations" or "endorsements", and it is imperative that readers understand that prior to any assumptions being made or conclusions being drawn. Thus, I would implore readers to consider my articles carefully and thoroughly, and to ask any questions they may have pertaining to publication purpose if not otherwise clearly defined. I will always do my best to respond in a timely fashion.
Lastly, I am a fervent proponent of the value brought to investments by behavioral finance theory, and I utilize this premise in all equities analysis.
Anonymity Disclosure: I am fully cognizant of the fact that some readers question the integrity and/or accountability of anonymous contributors. Please know that my preference for privacy is a two fold consideration; (1) I remain under a revolving open contract to consult for an entity where I signed a lifetime NCND agreement. In order not to risk violating any potential terms of that agreement, now or in the future, I maintain a very low web based profile. (2) I am a proponent of unbiased analysis being openly shared among prospective investors. However, in order to ensure no collisions occur between professional patronage and personal privacy, I have elected to utilize anonymity as the barrier between the two.
I currently work in the health care field. I am a long-term investor who conducts extensive research as part of my due diligence when considering a stock. My articles hope to provide unbiased background information to help others make an educated decision.
Although I recommend a diversified portfolio, I have a special interest in biomedical firms. Since biomedical investing is often very risky, I believe that research is especially important when investing in this industry. I find biomedical investing rewarding because these investments may not only yield high returns but also help save lives.
My trading experience includes over twenty five years of intense investment analysis, trend analysis and deep level due diligence studies. My interest is to find small company opportunities that have established funding sources, have a plan of action and are in the preliminary to first stages of pipeline development and execution. My coverage and investment interest includes biotech, small cap and emerging growth companies, regardless of sector.
I am currently a Junior at the George Washington University and have been investing since the sixth grade with my own money. I am very interested in the pharmaceutical sectors, but will buy just about any stock if I feel that the company is undervalued. I hope to provide some helpful insight, and to in turn learn a lot from the rest of the investment community.
I started investing while getting my Ph.D. at McGill University. My research was on behavioral correlates of neurological control of cardiovascular function. After 25 years as a Professor, I quit to do something more exciting and more difficult: live off of my investments. For quite some time, I specialized in Canadian Oil & Gas Trusts, other high income opportunities and special situations. In 2005, I founded the Trust Intelligence website to provide research and guidance to investors trying to wean them off of relying on sell-side analysts and to understand how to do due diligence from the point of view of an investor.
My personal investment focus, and that on my website, is still on special situations and income investments in Canada and the USA. I am focused on looking at relative value and great managements with businesses that have the characteristics to give them superior potential. While I retain interesting in the petroleum & income sectors I not focus on a few biotech special situations because they can be transformative for people's health and their net worth.
StockMatusow.com Writers are:
Scott Matusow; Team Leader, owner and founder of StockMatusow.com.
Scott is an independent investor/writer/trader and team leader of StockMatusow.com.
He has have about fifteen years of stock market experience which include trading, investing, and managing his family’s trust as well as his personal account.
Scott has had the most success in trading/investing in smaller cap growth companies. Because Scott is not 'officially trained' in the markets, he see things 'outside the box.' Scott uses his ability to read situations and emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements. Using these allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis.
Scott has his own online talk show which can be heard at www.scottmatusow.com/radio .
During market hours, we engage in talk about Stocks and Politics. After hours, Scott engages in a variety of talk issues from Poker, Sports, Politics, Current Events and whatever the chat room people wish to talk about.
Other places you can follow Scott are:
Kyle Dennis; writer, analyst, trader, website design, and team member of Stockmatusow.com.
Kyle has a Biology degree from the University of California Los Angeles (UCLA) and specializes in trading the biotechnology sector.
Kyle has extensive experience in researching, writing, and editing articles that have been published in scientific journals. He uses these experiences to write and comment about the potential of various biotechnology companies. Kyle specializes in evaluating trial success, drug potential, and market valuations.
As an investor/trader, Kyle likes to focus on chart analysis and investor/trader sentiment to identify good entry and exit points.
Kyle can also be followed at www.twitter.com/kylewdennis @kylewdennis
Michael Kovar; writer, editor, investor, trader and team member of stockmatusow.com
Michael has spent over ten years in financial roles with companies large and small. Recently, he spent time in a consulting role with Thomson Reuters legal headquarters in Eagan, MN. He currently works in an analyst position with a healthcare organization. Since 2011, Michael has worked with Scott Matusow to help research and edit articles for Stockmatusow.com.
Michael can be followed at www.twitter.com/MMK_3399 @MMK_3399
I have a Bachelors Degree In Business Administration. I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. With that In mind I seek stocks that have long term value! I primarily Like to Invest In biotechnology stocks and I accept the risks.
I Write for the Healthcare Sector and Stock market in general. I contribute to Seeking Alpha, Talk Markets, and CNA Finance. I run my own biotechnology website Biotechpicklist.com and in addition I post stock market news on my other website Wallstreetrain.com
I am a small-time writer/blogger who dreams big and enjoys researching and writing about biotechs and pharmaceuticals. My work experiences include food safety, water quality, pesticides, food additives, paints, plastics and pharmaceutical precursors. My focus as of late has been researching the treatment options for many cancers and prevention of their recurrence. Additional recent research has been in the stem cell field, an exciting field in its infancy but now becoming a teenager! My ongoing goal for investors is attempting to find under-the-radar or oversold pharmaceuticals or biotechs for investment potential.
I have an extensive background in Forex Account Management and a strong interest in the market. As a former Nurse, I have an interest in BioTech and Pharmaceutical companies that are emerging in the market.
I am an independent equity research analyst and consultant. I focus on finding small-cap biotech stocks where I believe there is favorable risk / reward because of misinformation, lack of information, or a potential fundamental turnaround. I provide detail analysis for investors and investor relations companies. I also provide due diligence and advisory services to companies. Some names I write on I invest in personally and will disclose my position. Names that have hired me to provide due diligence or advisory services I will disclose a business relationship. I previously worked for Zacks Investment Research from 2003 to 2015 as a Senior Biotechnology Analyst. Prior to Zacks, I spent 1999 to 2002 managing money with Eastover Capital in Charlotte, NC where I focused on large-cap equities, specializing in healthcare, energy, and technology. Prior to joining Eastover, I worked as a research scientist for TechLab, Inc., a biotechnology company focused on developing diagnostic kits and vaccines for infectious diseases, between 1995 and 1998. I also spent a year working at the Fralin Biotechnology Center, and a year working for a cancer researcher while at Virginia Tech. I have a B.S. in Biochemistry from Virginia Tech, with a B.A in Chemistry and a minor in Math. I have a M.B.A. in Finance, with a concentration in Securities Analysis, from Wake Forest University. I hold the Chartered Financial Analyst (CFA) designation.
I added stock and bond analysis to my IT consulting business at the request of a small cap investment specialist in 2002. For my own account I invest mainly in technology and biotechnology stocks, but occasionally I invest in industrial, retail and other stocks. My technology and investment web site is openicon.com. I still enjoy IT consulting and always have some sort of R&D project going on.
I have extensively researched the Biotech market the last few years. I look for undervalued stocks,cutting edge science, experienced management and tech to match. With innovation surrounding us in the information age and the advances being made in nano/tech, medicine and computers, I believe many breakthroughs will be made in the coming decade bringing innovation to many sectors in the market.
I am currently employed by a Fortune 20 company, on any given day I am assessing risk management and the financial health of various companies. My time is spent looking at charts and numbers all day and I specialize in statistical analysis. I use the writers of various finance sites for my investing ideas, then do my own research prior to investing.
Thanks to those of you that have given me feedback and responded to my messages. I have found the writers at Seeking Alpha to be very accommodating and informative.
Author of the critically acclaimed book, "Taking Charge With Value Investing (McGraw-Hill, 2013)" and the premium subscription service "Tipping The Scale" (as seen below). An analyst that ranks in the top 4% on both tipranks.com and Motley Fool CAPS for stock picking performance.
Tipping the Scale members gain access to the TTS Portfolio Tracker. Here, members see what I am buying and selling the minute it happens, along with what I have owned, bought, and sold historically. These are just a few of the features on the TTS Portfolio Tracker.
Tipping The Scale is an equity research platform that uses a numeric scale instead of the traditional "Buy, Hold, Sell" to identify the best investment opportunities in the market. Stock coverage is determined by market catalyst, and every company goes through a vigorous test in 10 different categories. The higher the total score, the bigger the upside. In addition, Tipping the Scale also provides a number of portfolio strategies to hedge the volatility of the market and protect from downside.
Check out my instablog for more information on the popular research service Tipping the Scale, including performance information, benefits, and how it all works.
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to building shareholder value.
View our website at www.MissionIR.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. The content we provide via Seeking Alpha may be part of our efforts to widen a client’s exposure. To read our full disclaimer, visit http://disclaimer.missionir.com.
I graduated from the University of Toronto with a BComm and am now working on developing a partnering business to help get the word out on disruptive investments. I want my research to provide timely and conclusive investment ideas that intend to deliver attractive yields to investors.
Keep updated with me on Twitter:
I enjoy following and capitalizing on investing opportunities primarily in the tech and healthcare industry. Most of my free time is spent conducting research on small-to-mid cap equities using a combination of fundamental data analysis and technical studies to come to conclusive results. I manage some money that I invest according to the above technique to ripen my exposure to the financial world.
Previously, I spent some time working for a major commercial construction company where I was responsible for running the back office, occasionally overlooking data and logistics. Most of my time was spent in a financial controller capacity.
I write because I believe in sharing my findings and opinions with those interested so they may come to their own conclusions and in turn spark an intelligent and beneficial discussion.
Interested in connecting? Shoot me a message